Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients

AIMS: Erlotinib is a tyrosine kinase inhibitor used in the treatment of non‐small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized medicine. The effect of erlotinib on CYP3A activity...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Svedberg, Anna, Vikingsson, Svante, Vikström, Anders, Hornstra, Niels, Kentson, Magnus, Branden, Eva, Koyi, Hirsh, Bergman, Bengt, Gréen, Henrik
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624433/
https://ncbi.nlm.nih.gov/pubmed/30945322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13953
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller